Related Experiment Video

Updated: Sep 22, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K

Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination

Robert J Wong1,2, Harvey W Kaufman3, Justin K Niles3

  • 1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 20, 2022
PubMed

Insights

Simplifying chronic hepatitis B (CHB) treatment criteria could increase patient eligibility for therapy. Many CHB patients not meeting current guidelines show significant fibrosis, highlighting the need for broader treatment access.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis B virus (HBV) DNA suppression is crucial for reducing hepatocellular carcinoma risk in chronic hepatitis B (CHB) patients.
  • Current CHB treatment criteria are complex, potentially delaying necessary therapy.
  • Simplifying these criteria can improve timely access to treatment.

Purpose of the Study:

  • To evaluate treatment eligibility patterns among US patients with CHB using various established guidelines.
  • To propose a stepwise simplification of CHB treatment criteria to enhance treatment accessibility.

Main Methods:

  • Analysis of 2016-2020 Quest Diagnostics data for patients meeting CHB criteria.
  • Evaluation of treatment eligibility using AASLD, EASL, APASL, and AATA criteria.
  • Assessment of significant fibrosis in treatment-ineligible patients.

Main Results:

  • Only a small percentage of CHB patients met AASLD (6.7%), EASL (6.2%), APASL (5.8%), and AATA (16.4%) criteria.
  • A notable proportion (7.7%-10.8%) of treatment-ineligible patients had significant fibrosis.
  • Proposed simplification increased eligibility from 10.3% to 87.2% by including patients with detectable HBV DNA.

Conclusions:

  • Many CHB patients not meeting current criteria exhibit significant fibrosis.
  • Simplifying criteria to include all patients with detectable HBV DNA can streamline eligibility assessment.
  • Broader treatment initiation is essential for improving CHB management and advancing HBV elimination efforts.
Abstract

Keywords:
AASLDEASLantiviralshepatitis B virustreatment eligibility

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.4K

Related Concept Videos

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
230
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
121
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
248
Drug Elimination: The Concept of Clearance01:06

Drug Elimination: The Concept of Clearance

Drug elimination refers to removing drugs from the body, either through urine by the kidneys or through bile by the liver. Drug clearance is a pharmacokinetic parameter that measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the plasma concentration of the drug.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
3.1K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.8K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
133